Tags

Type your tag names separated by a space and hit enter

Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
J Nephrol. 2005 Nov-Dec; 18(6):739-48.JN

Abstract

AIM

The objective of the study was to determine the situation concerning mineral metabolism and bone disease in hemodialysis (HD) patients living in the community of Valencia (Spain), as well as the clinical practices for bone disease control in relation to the laboratory targets recommended in the National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) guidelines.

METHODS

In December 2003, a cross-sectional study was performed including 2392 patients (1485 males and 907 females) from 43 different centers in the council of Valencia (the entire HD population). Mean age was 65.8 +/- 14 yrs. Cut-off levels for the study of calcium, phosphorus, calcium-phosphorus product (Ca x P) and parathyroid hormone (PTH) were performed following the recommendations of the K/DOQI guidelines.

RESULTS

The mean values for calcium were 9.57 +/- 0.7 mg/dL, phosphorus 4.97 +/- 1.5 mg/dL, intact PTH (iPTH) 297 +/- 353 pg/mL, Ca x P 47.5 +/- 15 mg2/dL2. Hypocalcemia (<8.4 mg/dL) was present in 5% of patients, whereas 17.8% of patients presented hypercalcemia (>10.2 mg/dL), 60.3% of whom received vitamin D. Hypophosphoremia (<3.5 mg/dL) was present in 16% of patients, and 29% of patients presented hyperphosphoremia (>5.5 mg/dL). Ca x P was <55 mg2/dL2 in 73% of patients. Thirty one percent of patients presented secondary hyperparathyroidism (HPTH >300 pg/mL), being severe in 12% (>600 pg/mL); 43% of patients presented iPTH <150 pg/mL. Only 7.3% of patients achieved the four recommendations provided in the K/DOQI guidelines. Vitamin D treatment was administered in 48% of patients.

CONCLUSIONS

The population undergoing dialysis in the community of Valencia achieved targets based on the clinical recommendations of the K/DOQI guidelines as follows: 45% of patients achieved targets for calcium, 55% for phosphorus, 73% for Ca x P and 26% for iPTH levels. Surprisingly, only 7.3% of patients achieved all four targets.

Authors+Show Affiliations

Department of Nephrology, Castellón General Hospital - Spain. maduell_fra@gva.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16358233

Citation

Maduell, Francisco, et al. "Assessment of Phosphorus and Calcium Metabolism and Its Clinical Management in Hemodialysis Patients in the Community of Valencia." Journal of Nephrology, vol. 18, no. 6, 2005, pp. 739-48.
Maduell F, Gorriz JL, Pallardo LM, et al. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. J Nephrol. 2005;18(6):739-48.
Maduell, F., Gorriz, J. L., Pallardo, L. M., Pons, R., & Santiago, C. (2005). Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. Journal of Nephrology, 18(6), 739-48.
Maduell F, et al. Assessment of Phosphorus and Calcium Metabolism and Its Clinical Management in Hemodialysis Patients in the Community of Valencia. J Nephrol. 2005 Nov-Dec;18(6):739-48. PubMed PMID: 16358233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia. AU - Maduell,Francisco, AU - Gorriz,Jose L, AU - Pallardo,Luis M, AU - Pons,Ramon, AU - Santiago,Carlos, AU - ,, PY - 2005/12/17/pubmed PY - 2006/1/25/medline PY - 2005/12/17/entrez SP - 739 EP - 48 JF - Journal of nephrology JO - J Nephrol VL - 18 IS - 6 N2 - AIM: The objective of the study was to determine the situation concerning mineral metabolism and bone disease in hemodialysis (HD) patients living in the community of Valencia (Spain), as well as the clinical practices for bone disease control in relation to the laboratory targets recommended in the National Kidney Foundation Dialysis Outcomes Quality Initiative (K/DOQI) guidelines. METHODS: In December 2003, a cross-sectional study was performed including 2392 patients (1485 males and 907 females) from 43 different centers in the council of Valencia (the entire HD population). Mean age was 65.8 +/- 14 yrs. Cut-off levels for the study of calcium, phosphorus, calcium-phosphorus product (Ca x P) and parathyroid hormone (PTH) were performed following the recommendations of the K/DOQI guidelines. RESULTS: The mean values for calcium were 9.57 +/- 0.7 mg/dL, phosphorus 4.97 +/- 1.5 mg/dL, intact PTH (iPTH) 297 +/- 353 pg/mL, Ca x P 47.5 +/- 15 mg2/dL2. Hypocalcemia (<8.4 mg/dL) was present in 5% of patients, whereas 17.8% of patients presented hypercalcemia (>10.2 mg/dL), 60.3% of whom received vitamin D. Hypophosphoremia (<3.5 mg/dL) was present in 16% of patients, and 29% of patients presented hyperphosphoremia (>5.5 mg/dL). Ca x P was <55 mg2/dL2 in 73% of patients. Thirty one percent of patients presented secondary hyperparathyroidism (HPTH >300 pg/mL), being severe in 12% (>600 pg/mL); 43% of patients presented iPTH <150 pg/mL. Only 7.3% of patients achieved the four recommendations provided in the K/DOQI guidelines. Vitamin D treatment was administered in 48% of patients. CONCLUSIONS: The population undergoing dialysis in the community of Valencia achieved targets based on the clinical recommendations of the K/DOQI guidelines as follows: 45% of patients achieved targets for calcium, 55% for phosphorus, 73% for Ca x P and 26% for iPTH levels. Surprisingly, only 7.3% of patients achieved all four targets. SN - 1121-8428 UR - https://www.unboundmedicine.com/medline/citation/16358233/Assessment_of_phosphorus_and_calcium_metabolism_and_its_clinical_management_in_hemodialysis_patients_in_the_community_of_Valencia_ L2 - https://medlineplus.gov/dialysis.html DB - PRIME DP - Unbound Medicine ER -